HopeStage
Back to all studies
WithdrawnNCT05119894

A Clinical Pharmacology Trial of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients With Schizophrenia

Medication studyAges 18–64
The study in practice

Understand this study

Who could participate?

This study is for people with schizophrenia. Listed age limits: 18 years to 64 years. Other eligibility criteria apply.

Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: November 22, 2021
Recruitment status
Withdrawn
Enrollment listed in the registry
0
Sponsor
Otsuka Pharmaceutical Co., Ltd.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
Not clearly listed
Age range
From 18 Years to 64 Years
Official registry ID
NCT05119894
Official title
Show the full official title

A Multicenter, Open-label, Clinical Pharmacology Trial to Determine the Pharmacokinetics, Tolerability, and Safety of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients With Schizophrenia

Recruitment & locations

Withdrawn

Locations not listed

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Otsuka Pharmaceutical Co., Ltd., a pharmaceutical company.

Does this study involve medication?

Yes. The study involves medication, including Brexpiprazole LAI: Dose 1, Brexpiprazole LAI: Dose 2, Brexpiprazole LAI: Dose 3 and Brexpiprazole LAI: Dose 4.

Who can participate?

This study is for people with schizophrenia. Listed age limits: 18 years to 64 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as withdrawn.

Want to explore more studies?

Explore studies